Inscripta, a startup that designs and sells gene-editing platforms, raised $150 million in its Series E funding round. The new capital will be used to fund growth, further develop its technology and improve distribution.
Gene-editing technology startup Inscripta raises $150M
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.